PR
Profound Medical Corp.
PROF · NASDAQ
$5.86 -2.33% (-$0.14)
1M -13.70%
Market Cap $214.0M
P/E Ratio -
Div. Yield -
ROE 56.16%
Bulios Fair Price
$3.44
41.3% downside
Current Price
$5.86
Undervalued Fair Value Overvalued
According to Bulios Fair Price, PROF is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
3/9Valuation
23 /100
Expensive P/B 4.30x
P/S 11.26x
P/FFO N/A
Growth
100 /100
Growing Book val. growth 20.50%
Rev. growth 34.84%
FCF growth N/A
Profitability
20 /100
Weak Op. margin 185.45%
Gross margin 71.79%
FCF margin 191.31%
Quality
4 /100
Poor ROA 52.33%
ROIC 61.48%
Asset turnover 0.30x
Debt
100 /100
Low Current ratio 6.45x
Debt/Equity 0.15x
Debt/Assets N/A
Stability
54 /100
Moderate EPS volatility 27.65%
Beta 0.53x
Profitable years 0
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about PROF
Online
Sector
Healthcare
Industry
Medical - Devices
CEO
Arun Swarup Menawat
Employees
162
Headquarters
Mississauga
Upcoming events
12 NOV
Earnings
Upcoming earnings report